Nevena Damjanov, MD
Hematology & Oncology · Philadelphia, PANPI 1518954395
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2019 at $15,496 and has fallen 71.2% since, to $4,457 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $560.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Merck$6K
- Exelixis Inc.$6K
- Sirtex Medical Inc$3K
- Eisai Inc.$2K
- Helsinn Therapeutics (U.S.), Inc.$2K
- plus $7K from 12 others
Across 14 payments — averaging $4512.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$55K
- Astellas Pharma Global Development$8K
- E.r. Squibb & Sons, L.L.C.$828
What the payments were for
- Consulting fees$19,20357%
- Speaking & faculty fees$8,25025%
- Travel & lodging$4,79114%
- Food & beverage$1,1753%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $6,870 |
| Merck | 15 | $6,487 |
| Exelixis Inc. | 10 | $6,474 |
| Sirtex Medical Inc | 2 | $2,600 |
| Eisai Inc. | 1 | $2,188 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $1,950 |
| Bayer | 3 | $1,734 |
| Regeneron Healthcare Solutions, Inc. | 1 | $1,490 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $1,350 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Taiho Oncology, Inc. | 1 | $550 |
| Sanofi | 1 | $350 |
| Sanofi-aventis U.S. LLC | 1 | $300 |
| Sobi, Inc | 1 | $200 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $100 |
| Ipsen Biopharmaceuticals, Inc | 1 | $100 |
| Seagen Inc. | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,617 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 16 | $231 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.